|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1973-11-9
|
|
pubmed:keyword |
http://linkedlifedata.com/resource/pubmed/keyword/Abortifacient Agents,
http://linkedlifedata.com/resource/pubmed/keyword/Abortion, Induced,
http://linkedlifedata.com/resource/pubmed/keyword/Biology,
http://linkedlifedata.com/resource/pubmed/keyword/DIARRHEA,
http://linkedlifedata.com/resource/pubmed/keyword/Endocrine System,
http://linkedlifedata.com/resource/pubmed/keyword/Genitalia,
http://linkedlifedata.com/resource/pubmed/keyword/Genitalia, Female,
http://linkedlifedata.com/resource/pubmed/keyword/Parity,
http://linkedlifedata.com/resource/pubmed/keyword/Physiology,
http://linkedlifedata.com/resource/pubmed/keyword/Pregnancy,
http://linkedlifedata.com/resource/pubmed/keyword/Pregnancy, Second Trimester,
http://linkedlifedata.com/resource/pubmed/keyword/Prostaglandins--administraction and...,
http://linkedlifedata.com/resource/pubmed/keyword/Prostaglandins--side effects,
http://linkedlifedata.com/resource/pubmed/keyword/Reproduction,
http://linkedlifedata.com/resource/pubmed/keyword/Urogenital System,
http://linkedlifedata.com/resource/pubmed/keyword/Uterine Effects,
http://linkedlifedata.com/resource/pubmed/keyword/Uterus,
http://linkedlifedata.com/resource/pubmed/keyword/Vomiting
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0090-6980
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
2
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
239-49
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:otherAbstract |
PIP: The contractile response of the midpregnant human uterus to a new (PG) prostaglandin analogue, 15(S)-methyl-PGF2alpha (15-me-PGF2alpha), was investigated and compared to the effect of natural PGF2alpha. It was found that the threshold dose of 15-me-PGF2alpha was around 10 mcg when given as a single intravenous injection, which is approximately 1/10 of the corresponding dose of PGF2alpha. It was also found that higher intravenous doses of 15-me-PGFalpha resulted in a uterine response of longer duration than that following PGF2alpha. Intramuscular injection of the analogue at doses of 1.0-1.5 mg induced a marked uterine stimulation sustained for 5-7 hours without causing local reaction. Intravenous infusion of 5 mcg/min of 15-me-PGF2alpha stimulated a level of uterine activity equivalent to that of 75 mcg/min of PGF1alpha. The incidence of gastrointestinal side effects was the same in the 2 treatment groups. However, there seemed to be a tendency toward a significantly higher abortion rate with the analogue.
|
|
pubmed:meshHeading |
pubmed-meshheading:4666626-Abortion, Induced,
pubmed-meshheading:4666626-Biological Assay,
pubmed-meshheading:4666626-Diarrhea,
pubmed-meshheading:4666626-Female,
pubmed-meshheading:4666626-Humans,
pubmed-meshheading:4666626-Injections, Intramuscular,
pubmed-meshheading:4666626-Injections, Intravenous,
pubmed-meshheading:4666626-Muscle Contraction,
pubmed-meshheading:4666626-Muscle Tonus,
pubmed-meshheading:4666626-Pregnancy,
pubmed-meshheading:4666626-Prostaglandins,
pubmed-meshheading:4666626-Time Factors,
pubmed-meshheading:4666626-Uterus,
pubmed-meshheading:4666626-Vomiting
|
|
pubmed:year |
1972
|
|
pubmed:articleTitle |
Response of the midpregnant human uterus to systemic administration of 15(S)-15-methyl-prostaglandin F2alpha.
|
|
pubmed:publicationType |
Journal Article
|
